Business Context and Reporting Period
Company: Lexaria Bioscience Corp.
Filing Type: Form 8-K (Current Report)
Date: November 27, 2017
Context: The filing reports unregistered sales of equity securities resulting from the exercise of warrants and a compensation option certificate. The company also noted upcoming participation in the 10th annual LD Micro Main Event in Los Angeles and the filing of its annual 10-K.
Key Financial Metrics
- Proceeds Received: US$118,913 from warrant and option exercises.
- Shares Issued: 415,187 common shares.
- Exercise Prices: Warrants exercised at US$0.14, US$0.273, and US$0.60; compensation option exercised at US$0.42.
- Outstanding Shares: 69,435,198 common shares following issuance.
- Transaction Costs: No commissions or placement fees were paid.
- Use of Proceeds: General corporate purposes.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the increase in outstanding common shares by 415,187 and the infusion of US$118,913 in capital. The filing does not provide comparative financial data against prior periods to assess changes in revenue or profitability.
Guidance, Outlook, and Risks
- Outlook: Management indicated attendance at the LD Micro Main Event (December 5-7) in Los Angeles.
- Regulatory Status: The securities issued were not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
- Participants: All exercises were conducted by third parties who are neither officers nor directors of the Company.
- Risks/Contingencies: No specific risks or contingencies were detailed beyond standard securities registration limitations.
Investor Verification Checklist
- Verify the total number of outstanding shares (69,435,198) in subsequent filings.
- Confirm the actual deployment of the US$118,913 proceeds for general corporate purposes.
- Review the upcoming 10-K filing for comprehensive financial statements, as this 8-K contains no revenue or profit data.
- Monitor the outcome of the presentation at the LD Micro Main Event for potential business developments.